Processing

Please wait...

Settings

Settings

1. WO2020002740 - DALBAVANCIN IN THE TREATMENT OF BACTERIAL RESPIRATORY TRACT INFECTIONS IN CHILDREN AND PEDIATRIC PATIENTS

Publication Number WO/2020/002740
Publication Date 02.01.2020
International Application No. PCT/ES2019/070453
International Filing Date 27.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14
Peptides containing saccharide radicals; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A61K 38/14 (2006.01)
A61P 31/04 (2006.01)
CPC
A61K 38/14
A61P 31/04
Applicants
  • SERVICIO ANDALUZ DE SALUD [ES/ES]; Avda. de la Constitucion, 18 41071 Sevilla, ES
Inventors
  • GÓMEZ DE RUEDA, Félix; ES
Agents
  • FUSTER, Gustavo; ES
Priority Data
P20183064427.06.2018ES
Publication Language Spanish (ES)
Filing Language Spanish (ES)
Designated States
Title
(EN) DALBAVANCIN IN THE TREATMENT OF BACTERIAL RESPIRATORY TRACT INFECTIONS IN CHILDREN AND PEDIATRIC PATIENTS
(ES) DALBAVANCINA EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS DEL TRACTO RESPIRATORIO EN NIÑOS Y PACIENTES PEDIÁTRICOS
(FR) DALBAVANCINE À UTILISER DANS LE TRAITEMENT D’INFECTIONS BACTÉRIENNES DES VOIES RESPIRATOIRES CHEZ DES ENFANTS ET DES PATIENTS PÉDIATRIQUES
Abstract
(EN)
The present invention relates to the use of a lipoglycopeptide antibiotic, dalbavancin, for the treatment of respiratory tract diseases, preferably pneumonia, in individuals aged under 18 years.
(ES)
La presente invención se refiere al empleo de un antibiótico lipoglicopéptido, la dalbavancina, para el tratamiento de enfermedades del tracto respiratorio, preferiblemente neumonía, en individuos menores de 18 años.
(FR)
La présente invention concerne l’utilisation d’un antibiotique lipoglycopeptidique, la dalbavancine, pour le traitement de maladies des voies respiratoires, de préférence la pneumonie, chez des individus de moins de 18 ans.
Latest bibliographic data on file with the International Bureau